The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment
{{output}}
Checkpoint blockade therapy (CBT) involving anti-PD1 antibodies represents the standard approach for cHL patients who do not respond to second-line therapy. Nonetheless, only 20% of relapsed/refractory (R/R) cHL patients treated with CBT achieve complete remis... ...
